Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic versus hemoglobin-triggered epoetin alfa for chemotherapy-associated anemia
ACTRN12614001082695Phase 3Completed
- Sponsor
- HeCOG
- Start
- Jan 2002
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epoetin alfa and Iron in chemotherapy-induced anaemia (CIA), sponsored by HeCOG. Primary endpoint: Long-term safety. Started Jan 2002; status: completed.
02
Drugs
epoetin alfaIron
03
Conditions
chemotherapy-induced anaemia (CIA)
Beyond the preview
Go deeper on ACTRN12614001082695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614001082695.